Astel­las' AML drug wins over CHMP — strength­en­ing lead on Dai­ichi Sankyo

Less than a year af­ter scor­ing a fast FDA OK for its pi­o­neer­ing acute myeloid leukemia drug gilter­i­tinib, Astel­las has snapped up a pos­i­tive rec­om­men­da­tion from Eu­ro­pean reg­u­la­tors fol­low­ing an ac­cel­er­at­ed as­sess­ment.

The CHMP thumbs up widens the gap be­tween Astel­las and Dai­ichi Sankyo, which has run in­to a road­block at the FDA when try­ing to field its own FLT3 tar­get­ed ther­a­py af­ter be­ing green-light­ed in Japan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER